{"id":"antithrombin-iii","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Chest pain"},{"rate":null,"effect":"Infusion site reactions"},{"rate":null,"effect":"Allergic reactions"}]},"_chembl":{"chemblId":"CHEMBL2108574","moleculeType":"Unknown"},"_dailymed":{"setId":"b2a9f856-3ef7-8da4-920c-f738e4f1f7d7","title":"THROMBATE III (ANTITHROMBIN III (HUMAN)) KIT THROMBATE III (ANTITHROMBIN III (HUMAN)) KIT [GRIFOLS USA, LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Antithrombin III is a serine protease inhibitor that circulates in blood and binds to and inactivates thrombin (factor IIa) and factor Xa, key enzymes in the coagulation cascade. This prevents excessive clot formation. The drug is derived from human plasma and is used as a replacement therapy in patients with antithrombin deficiency, either congenital or acquired, to restore anticoagulant capacity.","oneSentence":"Antithrombin III is a natural anticoagulant protein that inhibits blood clotting factors (thrombin and factor Xa) to prevent pathological thrombosis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:17:27.455Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Antithrombin III deficiency (congenital or acquired) for prevention and treatment of thromboembolism"},{"name":"Perioperative thromboembolism prophylaxis in patients with antithrombin deficiency"}]},"trialDetails":[{"nctId":"NCT07285460","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-12-18","conditions":"Hemophilia","enrollment":85},{"nctId":"NCT03560570","phase":"","title":"Study of Hemostasis in Patients With Congenital Disorder of Glycosylation","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2014-01-01","conditions":"Congenital Disorders of Glycosylation","enrollment":57},{"nctId":"NCT05662319","phase":"PHASE3","title":"A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2023-02-01","conditions":"Hemophilia","enrollment":91},{"nctId":"NCT06096116","phase":"PHASE3","title":"Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass","status":"RECRUITING","sponsor":"Octapharma","startDate":"2024-08-21","conditions":"Acquired Antithrombin Deficiency","enrollment":120},{"nctId":"NCT07036809","phase":"","title":"Assessment of Antithrombin III, Protein C, Protein S and D-dimer in Acute Leukemia","status":"COMPLETED","sponsor":"Muhamed Ahmed Abdelmoaty Muhamed Alhagrasy","startDate":"2023-06-01","conditions":"Acute Leukemia","enrollment":90},{"nctId":"NCT07350785","phase":"","title":"Prediction of Mortality and Morbidity After Hip Fracture Using Monocyte Distribution Width (MDW)","status":"RECRUITING","sponsor":"National and Kapodistrian University of Athens","startDate":"2024-12-01","conditions":"Sepsis, Osteoporotic Hip Fracture, Hip Fracture","enrollment":100},{"nctId":"NCT07276074","phase":"","title":"Evaluation of the Relevance of Antithrombin Prescriptions at Strasbourg University Hospitals","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2024-12-18","conditions":"Antithrombinemia","enrollment":160},{"nctId":"NCT04918173","phase":"PHASE3","title":"Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery","status":"RECRUITING","sponsor":"Octapharma","startDate":"2022-07-01","conditions":"Congenital Antithrombin Deficiency","enrollment":38},{"nctId":"NCT06145373","phase":"PHASE4","title":"A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-03-01","conditions":"Hemophilia A","enrollment":20},{"nctId":"NCT07098676","phase":"","title":"Haemodialysis Alters Hypercoagulability of Blood in Dialysis Patients","status":"ENROLLING_BY_INVITATION","sponsor":"Ai Peng","startDate":"2024-11-20","conditions":"Healthy Individuals (Controls), Vascular Surgery Patients With Acute Thrombosis, Dialysis Patients","enrollment":900},{"nctId":"NCT05484830","phase":"NA","title":"Coagulation in Acute Aortic Dissection","status":"COMPLETED","sponsor":"Ivy susanne Modrau, MD","startDate":"2022-11-01","conditions":"Acute Aortic Dissection, Coagulation Disorder","enrollment":26},{"nctId":"NCT04924322","phase":"PHASE2, PHASE3","title":"Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies","status":"RECRUITING","sponsor":"Yale University","startDate":"2022-05-11","conditions":"Deep Venous Thrombosis","enrollment":258},{"nctId":"NCT05794165","phase":"PHASE2","title":"Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism","status":"ENROLLING_BY_INVITATION","sponsor":"Bryan Cotton","startDate":"2023-09-27","conditions":"Trauma Injury, Thromboembolism, Venous Thromboembolism","enrollment":314},{"nctId":"NCT05895136","phase":"PHASE2","title":"A Novel COMBinATorial Therapy With Albumin and Enoxaparin in Patients With Decompensated Cirrhosis at High-risk of Poor Outcome (COMBAT Trial).","status":"RECRUITING","sponsor":"European Foundation for Study of Chronic Liver Failure","startDate":"2024-07-01","conditions":"Liver Cirrhosis, Decompensated Cirrhosis of Liver, Acute on Chronic Liver Failure (ACLF)","enrollment":90},{"nctId":"NCT00506519","phase":"PHASE2","title":"Recombinant Human Antithrombin (ATryn®) in the Treatment of Patients With DIC Associated With Severe Sepsis","status":"TERMINATED","sponsor":"LEO Pharma","startDate":"2007-07","conditions":"Disseminated Intravascular Coagulation","enrollment":25},{"nctId":"NCT05891899","phase":"","title":"Belgian Antithrombin Deficiency Registry","status":"NOT_YET_RECRUITING","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2025-05","conditions":"Antithrombin III Deficiency","enrollment":1000},{"nctId":"NCT00938288","phase":"PHASE1","title":"A Study of KW-3357 in Congenital Antithrombin Deficiency","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2009-04","conditions":"Congenital Antithrombin Deficiency","enrollment":16},{"nctId":"NCT02777580","phase":"PHASE4","title":"STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction","status":"COMPLETED","sponsor":"KU Leuven","startDate":"2017-08-01","conditions":"Myocardial Infarction","enrollment":609},{"nctId":"NCT05226442","phase":"PHASE2, PHASE3","title":"Safety and Feasibility of Argatroban As Anticoagulant in Adults with ECMO","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2021-12-01","conditions":"Extracorporeal Membrane Oxygenation Complication, Anticoagulants and Bleeding Disorders","enrollment":40},{"nctId":"NCT02251041","phase":"PHASE2","title":"Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL)","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2014-09","conditions":"Reperfusion Injury","enrollment":143},{"nctId":"NCT04912336","phase":"","title":"Extracorporeal Life Support and Modification of Hemostasis","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2021-05-28","conditions":"Bleeding Disorder, Extra Corporeal Life Support, Thrombosis","enrollment":43},{"nctId":"NCT06379126","phase":"","title":"The Diagnostic and Prognostic Value of TAT, PIC, tPAI·C and TM in Sepsis-induced Coagulopathy","status":"NOT_YET_RECRUITING","sponsor":"The First Hospital of Jilin University","startDate":"2024-04-20","conditions":"Sepsis-induced Coagulopathy","enrollment":210},{"nctId":"NCT05123326","phase":"","title":"Global Coagulation Assessment in Portal Vein Thrombosis and Budd-Chiari Syndrome","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2021-10-15","conditions":"Hepatic Vein Thromboses, Hepatic Venous Outflow Obstruction, Portal Vein Thrombosis","enrollment":300},{"nctId":"NCT06242353","phase":"","title":"Coagulopathy in Childhood Acute Lymphoblastic Leukaemia","status":"NOT_YET_RECRUITING","sponsor":"Karolinska University Hospital","startDate":"2024-03-01","conditions":"Acute Lymphoblastic Leukemia, Thrombosis, Bleeding","enrollment":100},{"nctId":"NCT05824013","phase":"","title":"Blood Coagulation Profile After Liver Resection.","status":"COMPLETED","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2023-04-12","conditions":"Coagulation Disorder","enrollment":46},{"nctId":"NCT06112262","phase":"EARLY_PHASE1","title":"Comparison Between Haparin and Herodin in HD","status":"NOT_YET_RECRUITING","sponsor":"Basma Rabiey","startDate":"2023-12-20","conditions":"Haemodialysis","enrollment":98},{"nctId":"NCT04182373","phase":"PHASE3","title":"KW-3357 Study in Patients With Early Onset Severe Preeclampsia","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2019-11-19","conditions":"Preeclampsia","enrollment":181},{"nctId":"NCT04651400","phase":"","title":"Observational, Retrospective Study to Evaluate Coagulation Changes and the Influence of Antithrombin III Treatment in Patients With Severe COVID-19 Infection","status":"COMPLETED","sponsor":"Octapharma","startDate":"2020-10-19","conditions":"Covid19","enrollment":300},{"nctId":"NCT05064267","phase":"","title":"Hemostatic Profiles in Pediatric CKD","status":"COMPLETED","sponsor":"Children's Healthcare of Atlanta","startDate":"2021-11-15","conditions":"Kidney Disease, Chronic, Pediatric Kidney Disease, Renal Insufficiency, Chronic","enrollment":8},{"nctId":"NCT00319228","phase":"PHASE2, PHASE3","title":"Safety, Pharmacokinetics and Efficacy of an ATIII Concentrate","status":"ACTIVE_NOT_RECRUITING","sponsor":"Grifols Biologicals, LLC","startDate":"2006-01","conditions":"Antithrombin III Deficiency","enrollment":30},{"nctId":"NCT05721066","phase":"","title":"Hemostatic Profile of Post COVID-19/Long COVID-19 Patients","status":"COMPLETED","sponsor":"IRCCS Policlinico S. Donato","startDate":"2022-04-12","conditions":"COVID-19, Post-acute COVID-19 Syndrome","enrollment":102},{"nctId":"NCT05541562","phase":"","title":"A Practical Nomogram Based on Systemic Inflammatory Markers for Predicting Portal Vein Thrombosis in Patients With Liver Cirrhosis","status":"COMPLETED","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2013-01-01","conditions":"Systemic Inflammatory Markers, Portal Vein Thrombosis","enrollment":478},{"nctId":"NCT04899232","phase":"PHASE2","title":"Antithrombin III in Infectious Disease Caused by COVID-19","status":"TERMINATED","sponsor":"Enrique Ginzburg","startDate":"2021-07-06","conditions":"Antithrombin III Deficiency, Covid19","enrollment":52},{"nctId":"NCT04219579","phase":"NA","title":"Antithrombin III Concentrate After Liver Transplantation","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2020-01-03","conditions":"Liver Transplant; Complications","enrollment":130},{"nctId":"NCT04879550","phase":"","title":"Prospective Investigation of Antithrombin III Deficiency in Adult Patients With ECMO","status":"COMPLETED","sponsor":"Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital","startDate":"2020-01-01","conditions":"Antithrombin III Deficiency, Extracorporeal Membrane Oxygenation Complication","enrollment":50},{"nctId":"NCT04055389","phase":"PHASE1","title":"Preventing de Novo Portal Vein Thrombosis With Antithrombin-III in Patients With Cirrhosis","status":"WITHDRAWN","sponsor":"Jonathan Stine","startDate":"2021-01-01","conditions":"Portal Vein Thrombosis, Cirrhosis, Liver","enrollment":""},{"nctId":"NCT03815773","phase":"","title":"PRospective Multicenter Observational Study on Transfusion Practice in Vv-ECMO Patients: The PROTECMO Study","status":"COMPLETED","sponsor":"The Mediterranean Institute for Transplantation and Advanced Specialized Therapies","startDate":"2018-12-01","conditions":"Extracorporeal Membrane Oxygenation Complication, Transfusion Related Complication, Hemorrhage","enrollment":656},{"nctId":"NCT04133844","phase":"","title":"Evaluation of Antithrombin Deficiency in Patients of Intensive Care Unit Placed on Extracorporeal Membrane Oxygenation","status":"COMPLETED","sponsor":"Rennes University Hospital","startDate":"2020-05-05","conditions":"Severe Cardiac Insufficiency","enrollment":50},{"nctId":"NCT04912193","phase":"","title":"Antithrombin III and Post-liver Transplantation Acute Kidney Injury","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2010-01-04","conditions":"Liver Transplantation and Antithrombin","enrollment":2395},{"nctId":"NCT04347824","phase":"","title":"Predict Adverse Events by Covid-19 Nephritis","status":"COMPLETED","sponsor":"University Hospital Goettingen","startDate":"2020-04-27","conditions":"Covid-19","enrollment":223},{"nctId":"NCT01886248","phase":"PHASE2","title":"Antithrombin-III for Patients With Hepatic Veno-occlusive Diseases Following Hematopoietic Stem Cell Transplantation","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2013-06","conditions":"Hepatic Veno-Occlusive Disease","enrollment":32},{"nctId":"NCT04745442","phase":"PHASE2","title":"Pilot Study of Antithrombin as Prophylaxis of Acute Respiratory Distress Syndrome in Patients With COVID-19","status":"COMPLETED","sponsor":"Maimónides Biomedical Research Institute of Córdoba","startDate":"2020-04-27","conditions":"Covid19, Severe Acute Respiratory Syndrome, Distress Respiratory Syndrome","enrollment":48},{"nctId":"NCT04567199","phase":"","title":"Influence of Cytosorb on Amount of Catecholamine and Mortality in Sepsis","status":"COMPLETED","sponsor":"Medical University Innsbruck","startDate":"2018-12-01","conditions":"Sepsis, Septic Shock, Cytokine Storm","enrollment":86},{"nctId":"NCT03844373","phase":"NA","title":"Tolerance and Acceptability Evaluation of STOCKHOLM","status":"COMPLETED","sponsor":"Aymes International Limited","startDate":"2018-11-02","conditions":"Malnutrition","enrollment":20},{"nctId":"NCT04582188","phase":"","title":"The Early Coagulopathy for the Prognosis in Sepsis","status":"UNKNOWN","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2020-11-05","conditions":"Sepsis, Coagulopathy, Outcome, Fatal","enrollment":200},{"nctId":"NCT03555383","phase":"","title":"Individualized Multimodal Hemostasis Evaluation Pyramid (IMHOTEP)","status":"COMPLETED","sponsor":"Semmelweis University","startDate":"2017-08-01","conditions":"Blood Loss, Postoperative, Liver Transplant, Hemostatic Disorder","enrollment":59},{"nctId":"NCT04535206","phase":"","title":"The Relationship Between the Lack of AT-Ⅲ, PC, PS Activity and PICC-related Thrombosis","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2018-08-30","conditions":"Central Venous Catheter Thrombosis","enrollment":112},{"nctId":"NCT04454775","phase":"","title":"Raloxifene on Coagulation System in the Postmenopausal Women","status":"COMPLETED","sponsor":"Karadeniz Technical University","startDate":"2005-12-01","conditions":"Raloxifene, Postmenopausal Women","enrollment":80},{"nctId":"NCT04380220","phase":"","title":"Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis","status":"UNKNOWN","sponsor":"Regina Elena Cancer Institute","startDate":"2017-09-07","conditions":"Multiple Sclerosis, Relapse","enrollment":80},{"nctId":"NCT02813538","phase":"","title":"Major Liver Resection: Early Clotting Disorders and Functional Impairment.","status":"COMPLETED","sponsor":"Hospital General Universitario Gregorio Marañon","startDate":"2016-02-05","conditions":"Hepatic Insufficiency, Blood Coagulation Disorders","enrollment":60},{"nctId":"NCT02181361","phase":"","title":"Hirudin Plus Aspirin in the Secondary Prevention of Cardioembolic Stroke Due to Nonvalvular Atrial Fibrillation","status":"COMPLETED","sponsor":"Xijing Hospital","startDate":"2014-06","conditions":"Cardioembolic Stroke, Atrial Fibrillation","enrollment":239},{"nctId":"NCT02103114","phase":"PHASE2","title":"Anti-thrombin III (ATIII) vs Placebo in Children (<7mo) Undergoing Open Congenital Cardiac Surgery","status":"COMPLETED","sponsor":"Duke University","startDate":"2014-06","conditions":"ATIII Deficiency","enrollment":45},{"nctId":"NCT01905748","phase":"NA","title":"Acute Phase Reactions and Thrombophilia in Pediatric Patients With Migraine","status":"UNKNOWN","sponsor":"HaEmek Medical Center, Israel","startDate":"2011-08","conditions":"Migraine, Thrombophilia","enrollment":15},{"nctId":"NCT00623623","phase":"PHASE3","title":"STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-03-01","conditions":"Myocardial Infarction","enrollment":1899},{"nctId":"NCT03208270","phase":"PHASE2, PHASE3","title":"Antithrombin Supplementation in ECMO","status":"COMPLETED","sponsor":"Policlinico Hospital","startDate":"2017-07-28","conditions":"Extracorporeal Membrane Oxygenation","enrollment":49},{"nctId":"NCT03287999","phase":"","title":"Inter Individual Variability in Initiation Pathway Activation and Regulation and Phenotypic Heterogeneity in Patients With Haemophilia A and B","status":"UNKNOWN","sponsor":"Royal Free Hospital NHS Foundation Trust","startDate":"2017-09-19","conditions":"Haemophilia","enrollment":250},{"nctId":"NCT02037555","phase":"PHASE2","title":"Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiopulmonary Bypass","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2014-06-26","conditions":"Cardiac Surgery, Cardiopulmonary Bypass","enrollment":425},{"nctId":"NCT02631174","phase":"PHASE1","title":"Evaluation Of The Pharmacokinetics Of Antithrombin III In Neonates And Infants Undergoing CPB And ECMO Support","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2015-06","conditions":"Extracorporeal Membrane Oxygenation Complication, Cardiopulmonary Bypass","enrollment":27},{"nctId":"NCT03090893","phase":"EARLY_PHASE1","title":"Response of Continuous Recombinant Antithrombin Infusion in Postcardiotomy ECMO Patients","status":"WITHDRAWN","sponsor":"Mayo Clinic","startDate":"2018-06-01","conditions":"Antithrombin Deficiency Type 2","enrollment":""},{"nctId":"NCT03580577","phase":"","title":"Risk Factors and Outcomes of Acute Venous Thromboembolism in Cirrhotic","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2018-09-01","conditions":"Liver Cirrhosis, Venous Thromboembolism","enrollment":60},{"nctId":"NCT03589430","phase":"","title":"Haemostatic Imbalance in Patients With Chronic Liver Disease","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2018-09-01","conditions":"Haemostasis Imbalance in Chronic Liver Disease","enrollment":100},{"nctId":"NCT02278575","phase":"PHASE4","title":"Atenativ Effect on Uterine Blood Flow and Preeclampsia","status":"WITHDRAWN","sponsor":"Vastra Gotaland Region","startDate":"2016-01","conditions":"Antithrombin III Deficiency","enrollment":""},{"nctId":"NCT03269019","phase":"","title":"Thrombotic Biomarkers to Predict Thrombosis in Heparin-induced Thrombocytopenia","status":"UNKNOWN","sponsor":"Wuhan Asia Heart Hospital","startDate":"2017-11-20","conditions":"Heparin-Induced Thrombocytopenia, Thrombosis, Biomarkers","enrollment":200},{"nctId":"NCT02059135","phase":"PHASE3","title":"Pharmacokinetics, Safety and Efficacy Study of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia","status":"COMPLETED","sponsor":"rEVO Biologics","startDate":"2014-07-11","conditions":"Preeclampsia","enrollment":120},{"nctId":"NCT02373293","phase":"","title":"Study to Assess the Prognostic Value of the Antithrombin III in the Acute Pancreatitis (AT-PROPANC)","status":"UNKNOWN","sponsor":"Francisco Javier García Borobia","startDate":"2015-01-18","conditions":"Acute Pancreatitis","enrollment":400},{"nctId":"NCT03188913","phase":"","title":"Factor XIII in Major Burns Coagulation","status":"UNKNOWN","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2017-06-19","conditions":"Burns, Coagulation Disorder, Factor XIII Deficiency","enrollment":20},{"nctId":"NCT02503267","phase":"","title":"\"Incidence and Consequences of Disorders of Glycosylation in Patients With Conotruncal and Septal Heart Defects\"","status":"UNKNOWN","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2015-07","conditions":"Congenital Heart Diseases, Conotruncal Defects, Congenital Disorder of Glycosylation","enrollment":300},{"nctId":"NCT01384903","phase":"PHASE3","title":"An Open-label Study of KW-3357","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2011-06","conditions":"Disseminated Intravascular Coagulation (DIC)","enrollment":221},{"nctId":"NCT01598883","phase":"PHASE1","title":"Understanding \"Heparin Resistance\" in Cardiac Surgery","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2012-06","conditions":"Cardiopulmonary Bypass, Altered Heparin Response","enrollment":504},{"nctId":"NCT00823082","phase":"PHASE2","title":"Use of Antithrombin in Cardiac Surgery With Cardiopulmonary Bypass","status":"COMPLETED","sponsor":"Instituto Grifols, S.A.","startDate":"2009-06","conditions":"Acquired Antithrombin III Deficiency, Coronary Artery Bypass","enrollment":200},{"nctId":"NCT00842621","phase":"","title":"Long Term Effects of Erythrocyte Lysis","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2009-03","conditions":"Sickle Cell Disease, Hemolytic Anemia","enrollment":390},{"nctId":"NCT01698567","phase":"PHASE1","title":"Antithrombin III in Infants With Cardiopulmonary Bypass (CPB)","status":"TERMINATED","sponsor":"University of Rochester","startDate":"2012-07","conditions":"Congenital Heart Disease","enrollment":6},{"nctId":"NCT01547728","phase":"PHASE4","title":"Response of Recombinant Antithrombin in Heparin Resistant Patients Undergoing Cardiac Surgery","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2012-02","conditions":"Thrombophilia Due to Acquired Antithrombin III Deficiency","enrollment":42},{"nctId":"NCT01649479","phase":"NA","title":"Comparative Prevalence of Psychiatric Manifestations in Purely Obstetrical Antiphospholipid Syndrome","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2013-04","conditions":"Antiphospholipid Syndrome","enrollment":20},{"nctId":"NCT01913444","phase":"PHASE4","title":"Pharmacokinetic Study of Recombinant AT III in Neonates Undergoing ECMO","status":"WITHDRAWN","sponsor":"Children's Hospital Los Angeles","startDate":"2013-07","conditions":"Neonates on ECMO","enrollment":""},{"nctId":"NCT01530737","phase":"PHASE3","title":"Antithrombin Enhancement May Improve Anticoagulation Efficiency in Infants Undergoing Cardiopulmonary Bypass for Cardiac Surgery","status":"COMPLETED","sponsor":"The Hospital for Sick Children","startDate":"2011-11","conditions":"Cardiopulmonary Bypass","enrollment":18},{"nctId":"NCT01158729","phase":"PHASE1","title":"Antithrombin III Supplementation for Cardiopulmonary Bypass in Neonates","status":"TERMINATED","sponsor":"Medical College of Wisconsin","startDate":"2011-08","conditions":"Postoperative Hemorrhage","enrollment":8},{"nctId":"NCT00056550","phase":"PHASE3","title":"Assess Incidence of Deep Vein Thrombosis(DVT)Following Administration of Recombinant Human Antithrombin (rhAT) to Hereditary Antithrombin(AT) Deficient Patients in High Risk Situations.","status":"COMPLETED","sponsor":"rEVO Biologics","startDate":"2002-12","conditions":"Antithrombin Deficiency, Congenital","enrollment":14},{"nctId":"NCT01382550","phase":"","title":"Prevention of Thrombosis Recurrence in Patients With Low Circulating Levels of Antithrombin.","status":"UNKNOWN","sponsor":"Federico II University","startDate":"1993-03","conditions":"Venous Thrombosis","enrollment":900},{"nctId":"NCT01670474","phase":"PHASE4","title":"Prolonged Hemodialysis Catheter Survival With Copolymer Coating and Rt-PA","status":"UNKNOWN","sponsor":"Centre Hospitalier du Centre du Valais","startDate":"2011-01","conditions":"Malfunction; Catheter, Thrombosis, Mechanical Complication of Hemodialysis Catheter","enrollment":240},{"nctId":"NCT00110513","phase":"PHASE3","title":"Recombinant Human Antithrombin (rhAT) in Patients With Hereditary Antithrombin Deficiency Undergoing Surgery or Delivery","status":"COMPLETED","sponsor":"rEVO Biologics","startDate":"2005-04","conditions":"Antithrombin III Deficiency","enrollment":18},{"nctId":"NCT00986635","phase":"","title":"Effect of Rivaroxaban on Coagulation Parameters- an ex Vivo Study","status":"COMPLETED","sponsor":"Johann Wolfgang Goethe University Hospital","startDate":"2009-09","conditions":"Differences in Laboratory Coagulation Parameters","enrollment":100},{"nctId":"NCT01201070","phase":"PHASE4","title":"Study of Administration Of Antithrombin in Patients With Low Plasmatic Levels of Antithrombin After Cardiac Surgery","status":"UNKNOWN","sponsor":"University of Bari","startDate":"2009-09","conditions":"Aortic Valve Insufficiency, Aortic Valve Stenosis, Mitral Valve Insufficiency","enrollment":90},{"nctId":"NCT00925639","phase":"PHASE3","title":"Effects of the Concentrated Extract of Soy on Coagulation Factors After Menopause","status":"UNKNOWN","sponsor":"Federal University of São Paulo","startDate":"2009-08","conditions":"Menopause","enrollment":84},{"nctId":"NCT00846274","phase":"PHASE1","title":"Phase1 Syudy to Evaluate the Safety and PK/PD of Human Antithrombin III","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2008-10","conditions":"Healthy","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Thrombate III","Thrombate","Anbinex","ATIII"],"phase":"marketed","status":"active","brandName":"Antithrombin III","genericName":"Antithrombin III","companyName":"Octapharma","companyId":"octapharma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Antithrombin III is a natural anticoagulant protein that inhibits blood clotting factors (thrombin and factor Xa) to prevent pathological thrombosis. Used for Antithrombin III deficiency (congenital or acquired) for prevention and treatment of thromboembolism, Perioperative thromboembolism prophylaxis in patients with antithrombin deficiency.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":5,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}